沙拉沙星对实验性感染猪链球菌病及大肠杆菌病的药效学

为兽医临床合理应用沙拉星（Ｓarafloxacin）提供理论依据，就其对实验性感染猪链球菌 病及大肠杆菌病的药效学进行了研究。以试管２倍稀释法测得沙拉沙星对兰氏Ｃ群类马链球菌（Ｃ５５１２０）和猪大肠杆菌（Ｏ５５）的最小抑菌浓度（ＭＩＣ）分别是０．８mg/Ｌ及０．０５mg/Ｌ。肌注给药对猪链球菌病和大肠杆菌病的试验性治疗结果不明，低、中 高剂量沙拉沙星组２．５、５、１０mg/kg）及环丙沙星组（５mg/kg）用药５d（每隔１２

Pharmacodynamics of Sarafloxacin against Experimentally Induced Streptococcosis suum and Colobacillosis in Pigs

The pharmacodynamics of sarafloxacin and ciprofl oxacin against experimentally induced streptococcosis and sarafloxacin, en rofloxacin against artificially induced colibacillosis in pigs were studied to provide the basis for their clinical use. Minimal inhibitory concentrations (MIC s) of above three drugs were determined for Streptococcus equisilis or Esc herichia coli by two-fold dilution method in vitro. Then, the therapeutic trials of s a rafloxacin (2.5, 5 and 10 mg/kg) and ciprofloxacin (5 mg/kg) against experimenta lly induced streptococcosis suum were carried out in pigs following intramuscula r administration for 5 days (twice daily). The therapeutic trials of sarafloxaci n (2.5, 5 and 10 mg/kg) and enrofloxacin (5 mg/kg) against artificially induced colibacillosis were performed in pigs following intramuscular administration for 3 successive days (twice daily). MICs of sarafloxacin and ciprofloxacin were 0. 8 and 0.8 mg/L for S.equisimilis, respectively. MICs of sarafloxacin and enr oflo xacin were 0.05 and 0.05 mg/L for E.coli, respectively. Following the treatm ent with sarafloxacin (2.5, 5 and 10 mg/kg) and ciprofloxacin (5 mg/kg) against Streptococcosis s uum for 5 days, the curative rates of the infected pigs were 60%, 80%, 90% and 6 0%, respectively. The mortality of the infected and untreated group was 40%. Fol lowing the treatment with sarafloxacin (2.5, 5 and 10 mg/kg) and enroloxacin (2. 5 mg/kg) against colobacillosis for 3 days, the curative rates of the infected p igs were 80%, 90%, 90% and 90%, respectively. The mortality of the infected and untreated group was 30%.